

2013 3rd Quarterly report for _____ ABBV _____

Date: 2013 11 13

Percentage change in Sales from year ago quarter _____ 4.4% _____

Percentage change in Earnings per Share from year ago quarter _____ NMF _____

Is company meeting our target sales & earnings estimates? yes

Pre-tax Profit on sales trend? (up, even, down) Even

Return on equity trends? (up, even, down) NMF

Debt? (up, even, down) Even

Current PE is _25.5 on my SSG; 14.4 in VL (Oct 11, 2013)

S&P 11/09/13: Trailing 12-Month P/E of 16.9, estimated 2013E P/E 15.3 __.

Where does it fall in my estimated High/low range of PE's? _____ Mid-range _____

Signature PE = _____ NA _____

Club cost basis for this stock is _____ \$25.29 _____. Current price is _____ \$47.85 _____
(from latest valuation)

Current fair value: Morningstar: _____ \$45.00 _____ S&P: _____ 12- month target \$55.00 _ Raised

My SSG Total Return is _____ 16.1 _____ Projected Average Return is _____ 7.9 _____

What will drive future growth?

Margin Expansion. Advancement of hepatitis C drugs which should reach market in 2015. Also promising new treatments for Parkinson's disease, leukemia, and endometriosis – all in late stage pipeline. Industry-wide: S&P sees benefits accruing from significant expansion of the market stemming from new coverage provided to up to 32 million currently uninsured Americans starting in 2014.

CORPORATE STRATEGY. AbbVie's strategic objectives include expanding Humira's sales through greater penetration of emerging markets, increased emphasis on earlier diagnosis of autoimmune patients, and new indications. ABBV also plans to advance its R&D pipeline through internal development or through collaborations and licensing agreements. From 2013 through 2016, the company plans to launch five significant new products. The company also plans to maximize efficiency by streamlining the supply chain and optimizing residual value when products near the end of exclusivity.

Additional comments: S&P: raised 12-month target price to \$55 based on enhanced valuations of Humira and advanced R&D pipeline. 11/9/13 reiterated BUY opinion. 4 Stars.

VL: 10/11/13: Outlook remains positive on Humira sales, roughly 50% of total revenue. Now working on cystic fibrosis therapies. ABBV remains a solid drug play for income and relative stability.

M Str 9/30/13: BUY at 31.50. Sell at \$60.75,

S&P: 11/09/13; dividend @ \$1.60/share; 12-month target price \$55/share

MicNOVA owns 31 shares; Dividend yield: 3.6%

Recommend: Buy More _yes_, Hold _____, Challenge with a better investment _____, Sell _____